Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Company reports third quarter results, Chrysalin product activities
December 12th, 2004
OrthoLogic Corp. announced results for the third quarter ended Sept. 30, 2004. It also updated its product development activities related to its Chrysalin Product Platform. OrthoLogic reported a net loss of $29.4 million, or $.80 per share, for the third quarter ended Sept. 30, 2004. For the nine months ended Sept. 30, 2004, OrthoLogic reported a net loss of $36.8 million, or $1.04 per share. The company said that third quarter and 9-month expenses for continuing operations compared with prior year increased as a result of the company's expanded efforts in research, development and clinical activities, as well as the Chrysalis Biotechnology, Inc....
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
